Hubro Therapeutics corporate mission is to develop and commercialize therapeutic and prophylactic cancer vaccines. The company has established a proprietary neo-peptide technology platform for cancer vaccines. The vaccines are based on peptides corresponding to neo-antigens resulting from frameshift mutation characteristically present in cancers associated with genetic microsatellite instability (MSI).
